Tweet
I have some RNA-seq data back and I am performing alignments with Bowtie2. The organism I am working with has an available transcriptome assembly as well as genome assembly. I am not interested in splice junctions or discovering novel genes... should I align to the transcriptome rather than the genome?
-
-
What kind of data do you have, and what is the goal of your experiment? -
I have several laser microdissected subtissues of a specialized plant structure called the funiculus that connects to a developing seed. I am working with canola. I am looking for differential expression between these different subtissues to explain specific functions of this structure as well as the specialization of its subcompartments.Comment
-
I would absolutely recommend mapping to the genome, in that case, since tissues might differentiate based on differential splicing as well as raw gene expression.
You shouldn't use Bowtie2 for RNA-seq; an RNA aligner such as Tophat (the most well known), STAR, or BBMap will be able to handle reads mapping to splice junctions. If you do not handle reads that cross introns, your results will be wrong because they will be biased against short exons; and if you map to the transcriptome, your results will be biased in favor of the isoforms that are in the particular transcriptome you selected, which will NOT contain all isoforms. The results of transcriptome-mapping are also biased in favor of genes that have more isoforms, if all are in the fasta.
So, if you want data that is unbiased, considers differential expression of gene isoforms in different tissue types, and discovering novel genes, you should map against the genome. You stated that you are not interested in splice junctions or discovering novel genes, but I don't really understand where RNA-seq research that ignores such things would be useful, at present.
I was just at a meeting with PacBio today where RNA-seq data from a model organism (meaning, it had a well-established transcriptome, from Illumina sequencing) indicated the existence of roughly double the number of isoforms as were present in the existing transcriptome. Whether these hypothetical isoforms are real is unclear; but either way, that's real science. Mapping exclusively to a transcriptome is not, since the hypothesis dictates the results.Comment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment